The role of VWF in FVIII/VWF concentrates: biochemical characterization of three different plasma-derived factor VIII products

被引：0
|
作者：
Cristofaro, Raimondode [1 ]
Lancellotti, Stefano [1 ]
Filippis, Vincenzode [2 ]
Acquasaliente, Laura [2 ]
Valsecchi, Carla [3 ]
Garagiola, Sabella [3 ]
Peyvandi, Flora [3 ]
机构：
[1] Catholic Univ, Sch Med, Haemophilia & Thrombosis Ctr, Dpt Med Sci, Rome, Italy
[2] Univ Padua, Dpt Pharmaceut & Pharmacol Sci, Sch Med, I-35100 Padua, Italy
[3] Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Angelo Bianchi Bonomi Hemophilia & Thrombosis Ctr, Milan, Italy
来源：
HAEMOPHILIA | 2014年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：26 / 26
页数：1
相关论文
共 50 条
  • [1] Effect of different monoclonal anti-FVIII antibodies on the haemostatic activity of plasma-derived and recombinant FVIII concentrates in absence and presence of VWF
    Pillitteri, D.
    Scholz, T.
    Krause, M.
    Kirchmaier, C.
    HAEMOPHILIA, 2010, 16 : 39 - 39
  • [2] Biochemical and immunochemical investigations of different plasma-derived and recombinant factor VIII products
    Josic, D
    Stadler, M
    Buchacher, A
    Schulz, P
    Schutz, R
    Wiry, G
    Schwinn, H
    THROMBOSIS AND HAEMOSTASIS, 1997, : P2095 - P2095
  • [3] Biological and biochemical assays to ensure the quality and safety of plasma-derived products: Factor VIII concentrates
    Radosevich, Miryana
    Burnouf, Thierry
    CURRENT PHARMACEUTICAL ANALYSIS, 2007, 3 (02) : 83 - 94
  • [4] A NEW VONWILLEBRAND-FACTOR (VWF) DEFECT IN A PATIENT WITH FACTOR-VIII (FVIII) DEFICIENCY BUT WITH NORMAL LEVELS AND MULTIMERIC PATTERNS OF BOTH PLASMA AND PLATELET VWF - CHARACTERIZATION OF ABNORMAL VWF/FVIII INTERACTION
    MAZURIER, C
    DIEVAL, J
    JORIEUX, S
    DELOBEL, J
    GOUDEMAND, M
    BLOOD, 1990, 75 (01) : 20 - 26
  • [5] Characterization of factor VIII-von Willebrand Factor (FVIII-VWF)-complex concentrates under shear stress
    Siekmann, J
    Schwarz, HP
    Turecek, L
    34TH HEMOPHILIA SYMPOSIUM, 2005, : 361 - 367
  • [6] Non-additive effect on thrombin generation when a plasma-derived factor VIII/von Willebrand factor (FVIII/VWF) is combined with emicizumab in vitro
    Bravo, Maria Isabel
    Raventos, Aida
    Perez, Alba
    Costa, Montserrat
    Willis, Todd
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2020, 18 (08) : 1934 - 1939
  • [7] Low incidence of FVIII inhibitors in patients treated with plasma derived FVIII concentrates and the outcomes of immune tolerance induction with FVIII/vWF concentrates
    Batorova, Angelika
    Bubanska, Eva
    Morongova, Anna
    Jankovicova, Denisa
    Prigancova, Tatiana
    HAEMOPHILIA, 2014, 20 : 47 - 48
  • [8] Use of a Plasma-Derived FVIII Product Containing VWF (VWF/PD-FVIII) in Primary Or Rescue Immune Tolerance Induction in Patients with Hemophilia A and Inhibitors
    Oldenburg, Johannes
    Haya, Saturnino
    Musso, Roberto
    Sanders, Joann M.
    Jimenez Yuste, Victor
    Sexauer, Charles
    Kurth, Margaret H.
    AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 : S159 - S159
  • [9] US Economic Impact of Recombinant FVIII Vs Plasma-Derived FVIII/VWF in Previously Untreated Hemophilia a Patients
    Sidonio, Robert F.
    Runken, M. Chris
    O'Day, Ken
    Meyer, Kellie
    Spears, Jeffrey
    BLOOD, 2017, 130
  • [10] Native plasma-derived FVIII/VWF complex has lower sensitivity to FVIII inhibitors than the combination of isolated FVIII and VWF proteins. Impact on Bethesda assay titration of FVIII inhibitors
    Bravo, M. I.
    Da Rocha-Souto, B.
    Grancha, S.
    Jorquera, J. I.
    HAEMOPHILIA, 2014, 20 (06) : 905 - 911
12345